Chugai Pharmaceuticals (4519-TO)

FierceBiotech  Mar 2  Comment 
Cleveland-based Athersys is pocketing a $10 million upfront payment from Chugai in exchange for licensing rights to the biotech's stem cell treatment for repairing stroke damage. The Japanese pharma company, which has close relations with Roche,...  Mar 2  Comment 
CLEVELAND, Ohio (TheStreet) -- Athersys found a partner willing to help develop its off-the-shelf stem cell therapy for stroke in Japan. The timing of the new partnership with Japanese drug maker Chugai is a bit odd, however, coming just one...
GenEng News  Mar 2  Comment 
Athersys will co-develop and co-commercialize its MultiStem® cell therapy for ischemic stroke in Japan by bringing in a partner, Chugai Pharmaceutical, in a deal that could net Athersys up to $205 million-plus. MultiStem is under Phase II...
FierceBiotech  Feb 2  Comment 
Japanese drugmaker Chugai Pharmaceutical is planning a major expansion of its Singapore research outpost, laying out 476 million Singapore dollars ($374 million) over 7 years as it hits the gas on antibody research.
FierceBiotech  Aug 25  Comment 
The news that Roche struck a deal to buy InterMune for $8.3 billion reportedly came at the expense of Chugai's investors.  Aug 18  Comment 
NEW YORK (TheStreet) -- Shares ofaChugai Pharmaceutica are down -4.65% to $75.40 after the company denied reports that its parent Roche Holding awas in talks to buy out the Japanese drugmaker to secure full control of its cancer and arthritis...
Reuters  Aug 18  Comment 
(Adds Chugai Pharmaceuticals, Dollar General, Sensata, Ingersoll-Rand and Mexichem)

You may also be interested in articles related to Chugai Pharmaceuticals (4519-TO):
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki